Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Jacek Gronwald; Andre Robidoux; Charmaine Kim-Sing; Nadine Tung; Henry T. Lynch; William D. Foulkes; Siranoush Manoukian; Peter Ainsworth; Susan L. Neuhausen; Rochelle Demsky; Andrea Eisen; Christian F. Singer; Howard Saal; Leigha Senter; Charis Eng; Jeffrey Weitzel; Pal Moller; Dawna M. Gilchrist; Olufunmilayo Olopade; Ophira Ginsburg; Ping Sun; Tomasz Huzarski; Jan Lubinski; Steven A. Narod; David Euhus; Judy Garber; Gad Rennert; Kevin Sweet; Ruth Gershoni-Baruch; Christine Rappaport; Edmond Lemire; Lovise Maehle; Dominique Stoppa-Lyonnet; Mary Daly; Sofia Merajver; Ava Kwong; Louise Bordeleau; Carey A. Cullinane; Eitan Friedman; Wendy McKinnon; Marie Wood; Daniel Rayson; Wendy Meschino; Jane McLennan; Josephine Wagner Costalas; Robert E. Reilly; Tuya Pal; Susan Vadaparampil; Kenneth Offit; Mark Robson; Noah Kauff; Jan Klijn; Claudine Isaacs; Fergus Couch; Cezary Cybulski; Tomasz Byrski; Ania Jakubowska; Seema Panchal; Sonia Nanda; Aletta Poll; Kelly Metcalfe; Barry Rosen; Susan Randall Armel; Albert Chudley; Gareth Evans; Joanne Blum; Beth Karlan; Dana Zakalik; John Lunn; Talia Donenberg; Barbara Pasini; Raluca N. Kurz; Taya Fallen

doi:10.1007/s10549-014-3026-3

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, Nadine Tung, Henry T. Lynch, William D. Foulkes, Siranoush Manoukian, Peter Ainsworth, Susan L. Neuhausen, Rochelle Demsky, Andrea Eisen, Christian F. Singer, Howard Saal, Leigha Senter, Charis Eng, Jeffrey Weitzel, Pal Moller, Dawna M. Gilchrist, Olufunmilayo Olopade, Ophira GinsburgPing Sun, Tomasz Huzarski, Jan Lubinski, Steven A. Narod^*, David Euhus, Judy Garber, Gad Rennert, Kevin Sweet, Ruth Gershoni-Baruch, Christine Rappaport, Edmond Lemire, Lovise Maehle, Dominique Stoppa-Lyonnet, Mary Daly, Sofia Merajver, Ava Kwong, Louise Bordeleau, Carey A. Cullinane, Eitan Friedman, Wendy McKinnon, Marie Wood, Daniel Rayson, Wendy Meschino, Jane McLennan, Josephine Wagner Costalas, Robert E. Reilly, Tuya Pal, Susan Vadaparampil, Kenneth Offit, Mark Robson, Noah Kauff, Jan Klijn, Claudine Isaacs, Fergus Couch, Cezary Cybulski, Tomasz Byrski, Ania Jakubowska, Seema Panchal, Sonia Nanda, Aletta Poll, Kelly Metcalfe, Barry Rosen, Susan Randall Armel, Albert Chudley, Gareth Evans, Joanne Blum, Beth Karlan, Dana Zakalik, John Lunn, Talia Donenberg, Barbara Pasini, Raluca N. Kurz, Taya Fallen

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.

Original language	English
Pages (from-to)	421-427
Number of pages	7
Journal	Breast Cancer Research and Treatment
Volume	146
Issue number	2
DOIs	https://doi.org/10.1007/s10549-014-3026-3
State	Published - Jul 2014

Funding

Funders	Funder number
Canadian Cancer Society Research Initiative
Morris and Horowitz Families Endowed Professor
National Institutes of Health
National Cancer Institute	R01CA074415
Canadian Breast Cancer Research Alliance
icare	IBG09-34198

Keywords

BRCA1
BRCA2
Breast cancer
Oophorectomy
Tamoxifen

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-014-3026-3

Cite this

Gronwald, J., Robidoux, A., Kim-Sing, C., Tung, N., Lynch, H. T., Foulkes, W. D., Manoukian, S., Ainsworth, P., Neuhausen, S. L., Demsky, R., Eisen, A., Singer, C. F., Saal, H., Senter, L., Eng, C., Weitzel, J., Moller, P., Gilchrist, D. M., Olopade, O., ... Fallen, T. (2014). Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 146(2), 421-427. https://doi.org/10.1007/s10549-014-3026-3

@article{697f9f9971074c5399722835bd489984,

title = "Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers",

abstract = "Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.",

keywords = "BRCA1, BRCA2, Breast cancer, Oophorectomy, Tamoxifen",

author = "Jacek Gronwald and Andre Robidoux and Charmaine Kim-Sing and Nadine Tung and Lynch, {Henry T.} and Foulkes, {William D.} and Siranoush Manoukian and Peter Ainsworth and Neuhausen, {Susan L.} and Rochelle Demsky and Andrea Eisen and Singer, {Christian F.} and Howard Saal and Leigha Senter and Charis Eng and Jeffrey Weitzel and Pal Moller and Gilchrist, {Dawna M.} and Olufunmilayo Olopade and Ophira Ginsburg and Ping Sun and Tomasz Huzarski and Jan Lubinski and Narod, {Steven A.} and David Euhus and Judy Garber and Gad Rennert and Kevin Sweet and Ruth Gershoni-Baruch and Christine Rappaport and Edmond Lemire and Lovise Maehle and Dominique Stoppa-Lyonnet and Mary Daly and Sofia Merajver and Ava Kwong and Louise Bordeleau and Cullinane, {Carey A.} and Eitan Friedman and Wendy McKinnon and Marie Wood and Daniel Rayson and Wendy Meschino and Jane McLennan and Costalas, {Josephine Wagner} and Reilly, {Robert E.} and Tuya Pal and Susan Vadaparampil and Kenneth Offit and Mark Robson and Noah Kauff and Jan Klijn and Claudine Isaacs and Fergus Couch and Cezary Cybulski and Tomasz Byrski and Ania Jakubowska and Seema Panchal and Sonia Nanda and Aletta Poll and Kelly Metcalfe and Barry Rosen and Armel, {Susan Randall} and Albert Chudley and Gareth Evans and Joanne Blum and Beth Karlan and Dana Zakalik and John Lunn and Talia Donenberg and Barbara Pasini and Kurz, {Raluca N.} and Taya Fallen",

note = "Funding Information: Acknowledgements We would like to thank study coordinators Adriana Valentini, Marcia Llacuachaqui, and Alejandra Ragone, as well as Jennifer Ng, Kristi De Buono, Kate Bisnaire, Dina Nikitina, Anneli Loo, Bita Khorram, Dina Gordon, Courtney May, Michelle Jones, Jose Miguel Lozano and Linda Steele who helped with the data collection and data entry. Supported by grants from the Canadian Breast Cancer Research Alliance and the Canadian Cancer Society Research Initiative and an ICARE grant IBG09-34198 awarded to T. Pal. SLN is the Morris and Horowitz Families Endowed Professor, and the work was supported by NIH R01 CA74415.",

year = "2014",

month = jul,

doi = "10.1007/s10549-014-3026-3",

language = "אנגלית",

volume = "146",

pages = "421--427",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "2",

}

Gronwald, J, Robidoux, A, Kim-Sing, C, Tung, N, Lynch, HT, Foulkes, WD, Manoukian, S, Ainsworth, P, Neuhausen, SL, Demsky, R, Eisen, A, Singer, CF, Saal, H, Senter, L, Eng, C, Weitzel, J, Moller, P, Gilchrist, DM, Olopade, O, Ginsburg, O, Sun, P, Huzarski, T, Lubinski, J, Narod, SA, Euhus, D, Garber, J, Rennert, G, Sweet, K, Gershoni-Baruch, R, Rappaport, C, Lemire, E, Maehle, L, Stoppa-Lyonnet, D, Daly, M, Merajver, S, Kwong, A, Bordeleau, L, Cullinane, CA, Friedman, E, McKinnon, W, Wood, M, Rayson, D, Meschino, W, McLennan, J, Costalas, JW, Reilly, RE, Pal, T, Vadaparampil, S, Offit, K, Robson, M, Kauff, N, Klijn, J, Isaacs, C, Couch, F, Cybulski, C, Byrski, T, Jakubowska, A, Panchal, S, Nanda, S, Poll, A, Metcalfe, K, Rosen, B, Armel, SR, Chudley, A, Evans, G, Blum, J, Karlan, B, Zakalik, D, Lunn, J, Donenberg, T, Pasini, B, Kurz, RN & Fallen, T 2014, 'Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers', Breast Cancer Research and Treatment, vol. 146, no. 2, pp. 421-427. https://doi.org/10.1007/s10549-014-3026-3

TY - JOUR

T1 - Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

AU - Gronwald, Jacek

AU - Robidoux, Andre

AU - Kim-Sing, Charmaine

AU - Tung, Nadine

AU - Lynch, Henry T.

AU - Foulkes, William D.

AU - Manoukian, Siranoush

AU - Ainsworth, Peter

AU - Neuhausen, Susan L.

AU - Demsky, Rochelle

AU - Eisen, Andrea

AU - Singer, Christian F.

AU - Saal, Howard

AU - Senter, Leigha

AU - Eng, Charis

AU - Weitzel, Jeffrey

AU - Moller, Pal

AU - Gilchrist, Dawna M.

AU - Olopade, Olufunmilayo

AU - Ginsburg, Ophira

AU - Sun, Ping

AU - Huzarski, Tomasz

AU - Lubinski, Jan

AU - Narod, Steven A.

AU - Euhus, David

AU - Garber, Judy

AU - Rennert, Gad

AU - Sweet, Kevin

AU - Gershoni-Baruch, Ruth

AU - Rappaport, Christine

AU - Lemire, Edmond

AU - Maehle, Lovise

AU - Stoppa-Lyonnet, Dominique

AU - Daly, Mary

AU - Merajver, Sofia

AU - Kwong, Ava

AU - Bordeleau, Louise

AU - Cullinane, Carey A.

AU - Friedman, Eitan

AU - McKinnon, Wendy

AU - Wood, Marie

AU - Rayson, Daniel

AU - Meschino, Wendy

AU - McLennan, Jane

AU - Costalas, Josephine Wagner

AU - Reilly, Robert E.

AU - Pal, Tuya

AU - Vadaparampil, Susan

AU - Offit, Kenneth

AU - Robson, Mark

AU - Kauff, Noah

AU - Klijn, Jan

AU - Isaacs, Claudine

AU - Couch, Fergus

AU - Cybulski, Cezary

AU - Byrski, Tomasz

AU - Jakubowska, Ania

AU - Panchal, Seema

AU - Nanda, Sonia

AU - Poll, Aletta

AU - Metcalfe, Kelly

AU - Rosen, Barry

AU - Armel, Susan Randall

AU - Chudley, Albert

AU - Evans, Gareth

AU - Blum, Joanne

AU - Karlan, Beth

AU - Zakalik, Dana

AU - Lunn, John

AU - Donenberg, Talia

AU - Pasini, Barbara

AU - Kurz, Raluca N.

AU - Fallen, Taya

N1 - Funding Information: Acknowledgements We would like to thank study coordinators Adriana Valentini, Marcia Llacuachaqui, and Alejandra Ragone, as well as Jennifer Ng, Kristi De Buono, Kate Bisnaire, Dina Nikitina, Anneli Loo, Bita Khorram, Dina Gordon, Courtney May, Michelle Jones, Jose Miguel Lozano and Linda Steele who helped with the data collection and data entry. Supported by grants from the Canadian Breast Cancer Research Alliance and the Canadian Cancer Society Research Initiative and an ICARE grant IBG09-34198 awarded to T. Pal. SLN is the Morris and Horowitz Families Endowed Professor, and the work was supported by NIH R01 CA74415.

PY - 2014/7

Y1 - 2014/7

N2 - Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.

AB - Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - Oophorectomy

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84904129599&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3026-3

DO - 10.1007/s10549-014-3026-3

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 24951267

AN - SCOPUS:84904129599

SN - 0167-6806

VL - 146

SP - 421

EP - 427

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this